rifampin
rifampin: 12 clinical trials tracked.
rifampin evidence translation
What we can confirm
12 tracked trials
What it means
What to watch
Prepared research question
What is verified about rifampin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 7 study sponsors
Related indications
Clinical Trials (12)showing 10 most recent
An Open-label, Phase 1 Study to Characterize the Effects of Rifampin on the Pharmacokinetics of MK-8527 in Adult Participants With Latent Tuberculosis Infection
Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MK-8527
An Open-Label Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
Primary endpoint: Pharmacokinetics Parameter (PK): Cmax of INCB161734
Shortened Regimen for Drug-susceptible TB in Children
Primary endpoint: TB disease-free survival at 48-weeks
Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated Severe Acute Malnutrition
Primary endpoint: Death or first hospitalisation or failed nutritional recovery within 24 weeks post-randomisation
A Phase IIc, Open-Label, Randomized Controlled Trial of Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis (PRESCIENT)
Primary endpoint: Time to stable liquid culture conversion
A Phase 1, Open Label, Fixed Sequence Study to Assess the Pharmacokinetics of Brensocatib When Administered Alone and With Multiple Doses of Rifampin (CYP3A Inducer) or Esomeprazole (Proton Pump Inhibitor) in Healthy Subjects
Primary endpoint: Parts 1 and 2: Area Under the Concentration-time (AUC) of Brensocatib in Plasma
A Multicenter, Phase 2b/c, Open-label, Randomized, Dose-finding Trial to Evaluate the Safety and Efficacy of a 4 Month Regimen of OPC-167832 in Combination With Delamanid and Bedaquiline in Subjects With Drug-susceptible Pulmonary Tuberculosis in Comparison With Standard Treatment
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, TEAEs Related to Study Drug, TEAEs Leading to Study Discontinuation, TEAEs Leading to Death, and All Grade TEAEs Based on DAIDS Criteria
A Phase 2/3, Multicenter, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
Primary endpoint: Number of Participants With Sputum Culture Conversion in Mycobacteria Growth Indicator Tube (MGIT) at Week 24
Phase 1, Open-label, Parallel, 2-arm, Fixed-sequence Study to Investigate the Effect of Coadministration of CYP3A4 Inhibitor and CYP3A4 Inducer on the Pharmacokinetics, Safety, and Tolerability of KBP-5074 in Healthy Subjects
Primary endpoint: Pharmacokinetic Parameter: Maximum observed concentration (Cmax)
A Phase 1, Single-center, Open-label, Two-cohort, Two-period, One-sequence, Two Treatment, Drug-drug Interaction Study of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Subjects
Primary endpoint: Pharmacokinetics: AUClast of SAR442168